Phuturdex › Diseases › Stress incontinence
Drugs in development · updated 13 November 2026
Stress incontinence: drugs in development
What it is
Stress incontinence, also known as stress urinary incontinence (SUI) or effort incontinence is a form of urinary incontinence. It is due to inadequate closure of the bladder outlet by the urethral sphincter.
Description not checked by Phuturdex: excerpt from the introduction of the article “Stress incontinence” on English Wikipedia, en.wikipedia.org · version of 30 October 2026 · licence CC BY-SA 4.0.
As of 13 November 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for stress incontinence. One is experimental, that is not yet approved in the United States.
In Phuturdex every drug has its map of sites in Europe, every trial and its alerts, and you get an email when something changes. Full access free until 31 March 2027, no card needed.
Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BerobenatidePF-08653944, MET097 | III | 1 | NCT07932925 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OrforglipronFoundayo®, LY3502970 | III | 1 | NCT07202884 |
| Testosterone cypionateAzmiro® | II | 1 | NCT06111209 |
Sorted by most advanced phase and number of active trials.
Sites in Europe
31 sites of the active trials in 3 European countries, 22 recruiting.
- Romania16
- Czechia9
- Poland6
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Urologic Diseases 766 drugs
- Female urogenital disease 1,195 drugs
- Female urogenital diseases and pregnancy complications 1,234 drugs
- Urogenital Diseases 1,543 drugs
- Male urogenital disease 1,088 drugs
- Lower urinary tract symptoms 19 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 13 November 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D014550 “Urinary Incontinence, Stress”.